Revefenacin
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Revefenacin (Theravance Biopharma/Mylan) is a long-acting muscarinic antagonist (LAMA) that will join a very crowded COPD market. The drug will be in direct competition with the gold-standard therapy Spiriva (tiotropium; Boehringer Ingelheim), as well as a host of other LAMA therapies that are available for the treatment of COPD. Revefenacin’s positive clinical trial data may help its uptake, but its late entry to the COPD market and its formulation as a nebulized therapy will significantly limit its potential.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 revefenacin : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
9 Figure 1: Datamonitor Healthcare’s drug assessment summary of revefenacin for COPD
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of revefenacin for COPD
LIST OF TABLES
5 Table 1: Revefenacin drug profile
7 Table 2: Revefenacin Phase III data in COPD
8 Table 3: Revefenacin Phase III trial in COPD
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Trimbow 
Sign up to the